EGFR and periodontitis: In summary, our findings demonstrate that EPO‐EVs, highly enriched with miR‐5107‐5p, partially mitigate inflammatory bone loss in periodontitis through the EGFR/RhoA axis, suggesting a potential therapeutic target for periodontitis treatment.